Shots:

• EC has released Takeda from the obligation to divest SHP647 & its associated rights. Takeda will discontinue the clinical study of SHP647 and will provide an opportunity to the participants to access in a PTA study
• In 2018- EC approved its proposed acquisition of Shire with a condition. To avoid overlap in IBD b/w Takeda’s Entyvio (vedolizumab) and Shire’s SHP647- Takeda committed to divest SHP647 which became effective on Jan 08- 2019
• Following the completion of the Shire acquisition- EC concluded that there is no competition concern b/w the drugs- thus Takeda’s obligation to divest SHP647 was no longer justified and the EC waived the commitment

 ­ Ref: Takeda | Image: Takeda